Handelsbanken Fonder Ab Ionis Pharmaceuticals Inc Transaction History

Handelsbanken Fonder Ab

$25.3 Billion
Q3 2024

A detailed history of Handelsbanken Fonder Ab transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 43,011 shares of IONS stock, worth $1.74 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

43,011

Previous 33,911 26.83%

Holding current value

$1.74 Million

Previous $1.62 Million 6.62%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 04, 2024	BUY	$40.06 - $51.86 $364,546 - $471,926	9,100 Added 26.83%	43,011 $1.72 Million
Q1 2024 May 13, 2024	BUY	$42.03 - $53.55 $290,007 - $369,495	6,900 Added 25.55%	33,911 $1.47 Million
Q4 2023 Feb 01, 2024	BUY	$43.39 - $51.63 $138,848 - $165,216	3,200 Added 13.44%	27,011 $1.37 Million
Q3 2023 Oct 19, 2023	SELL	$38.5 - $47.13 $265,650 - $325,197	-6,900 Reduced 22.47%	23,811 $1.08 Million
Q2 2023 Aug 02, 2023	BUY	$34.73 - $43.33 $423,705 - $528,626	12,200 Added 65.91%	30,711 $1.26 Million
Q2 2022 Aug 03, 2022	BUY	$31.71 - $43.0 $152,208 - $206,400	4,800 Added 35.01%	18,511 $685,000
Q1 2022 May 11, 2022	SELL	$29.88 - $37.04 $319,716 - $396,328	-10,700 Reduced 43.83%	13,711 $508,000
Q2 2021 Aug 03, 2021	BUY	$34.54 - $47.25 $48,356 - $66,150	1,400 Added 6.08%	24,411 $974,000
Q1 2021 Apr 29, 2021	SELL	$42.51 - $63.78 $153,036 - $229,608	-3,600 Reduced 13.53%	23,011 $1.04 Million
Q4 2020 Feb 11, 2021	BUY	$45.3 - $60.27 $194,790 - $259,161	4,300 Added 19.27%	26,611 $1.51 Million
Q2 2020 Aug 13, 2020	BUY	$46.85 - $61.05 $1.05 Million - $1.36 Million	22,311 New	22,311 $1.32 Million

Others Institutions Holding IONS

# of Institutions

389

Shares Held

125M

Call Options Held

2.25M

Put Options Held

510K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.73B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Account

Handelsbanken Fonder Ab Ionis Pharmaceuticals Inc Transaction History